Sanofi
Sanofi (SNYNF): 60 pipeline candidates. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
N/A
Lead: Phase 3
60 candidates
N/A
N/A
A transparent, data-derived signal for Sanofiacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$106.5B
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (60 candidates)
| Drug | Phase |
|---|---|
| activated charcoal | Phase 3 |
| alemtuzumab | — |
| alirocumab | — |
| amcenestrant | Phase 2 |
| avalglucosidase alfa | Phase 3 |
| belantamab mafodotin | Phase 1/Phase 2 |
| bivv020 | Phase 1 |
| diphenhydramine | Phase 2 |
| duvakitug | Phase 3 |
| efluelda pre-filled syringe | — |
Showing 10 of 60 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Sanofi's pipeline?
Sanofi (SNYNF) has 60 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sanofi's lead drug candidate?
Sanofi's most advanced tracked candidate is activated charcoal (Phase 3) for Multiple Sclerosis.
What is Sanofi's market capitalization?
Sanofi's market capitalization is approximately $106.5B.
Who is the CEO of Sanofi?
Ms. Belen Garijo Lopez M.D. is the chief executive officer of Sanofi (SNYNF).
Get the full picture on Sanofi
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.